Chemocentryx Stock Story

CCXI
 Stock
  

USD 50.52  0.09  0.18%   

As many of us are excited about healthcare space, it is fair to concentrate on Chemocentryx within current market trends. As expected, Chemocentryx is starting to reaffirm its true potential as stockholders are becoming more and more confident in the future outlook. Much of the drifts of the company stock price movements has been an effusion of what is happening in the market overall. The occurrence of stable basic indicators of the company implies a mid-run price swing for stockholders of Chemocentryx. The stock goes through a very aggressive trading activities.
Published over a month ago
View all stories for Chemocentryx | View All Stories

Chemocentryx Sentiment by News Outlets

benzinga news
zacks News
Investors Business Daily at Macroaxis
Investing News at Macroaxis
Barrons News
fool News
reuters
news
prnewswire News
Macroaxis News: globenewswire.com
news

Chemocentryx Historical Investor Sentiment

Investor biases related to Chemocentryx's public news can be used to forecast risks associated with investment in Chemocentryx. The trend in average sentiment can be used to explain how an investor holding Chemocentryx can time the market purely based on public headlines and social activities around Chemocentryx. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Chemocentryx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Chemocentryx's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Chemocentryx's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Chemocentryx.

Chemocentryx Twitter Pulse

Investors have realized that leveraging social media to get the fastest information affecting stock prices isn't a theory anymore, it is a reality, and Twitter offers a platform that can outpace even the most trustworthy news aggregators. The influence of social media outlets on stock markets and stock prices of entities such as Chemocentryx has been proven in recent years. We extract public sentiment from Twitter posts that could be utilized to determine whether Chemocentryx's prices will increase or decrease.
Twitter's metrics such as likes, followers, and engagement can be good indicators of the reliance and probability of reaction to a specific tweet regarding Chemocentryx. Our Twitter sentiment analysis of Chemocentryx Stock helps investors make informed decisions by leveraging the power of the community. It is a perfect supplementary tool for any beginner or an experienced trader.

Chemocentryx Maximum Pain Price across 2022-08-19 Option Contracts

Chemocentryx's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Chemocentryx close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Chemocentryx's options.

Our current technical analysis of Chemocentryx (NASDAQ:CCXI)

Chemocentryx's average rating is Buy from 6 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Chemocentryx market sentiment investors' perception of the future value of Chemocentryx. Let us look at a few aspects of Chemocentryx technical analysis. About 76.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.74. Chemocentryx had not issued any dividends in recent years.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Chemocentryx. In general, we focus on analyzing Chemocentryx stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Chemocentryx's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Chemocentryx's intrinsic value. In addition to deriving basic predictive indicators for Chemocentryx, we also check how macroeconomic factors affect Chemocentryx price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Chemocentryx's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Chemocentryx in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Chemocentryx. Your research has to be compared to or analyzed against Chemocentryx's peers to derive any actionable benefits. When done correctly, Chemocentryx's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Chemocentryx.

How important is Chemocentryx's Liquidity

Chemocentryx financial leverage refers to using borrowed capital as a funding source to finance Chemocentryx ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Chemocentryx financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Chemocentryx's total debt and its cash.

How does Chemocentryx utilize its cash?

To perform a cash flow analysis of Chemocentryx, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Chemocentryx is receiving and how much cash it distributes out in a given period. The Chemocentryx cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Chemocentryx Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (75.62 Million)

Acquisition by Herron Jennifer Lyn of 17237 shares of Chemocentryx subject to Rule 16b-3

Legal trades by Chemocentryx insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Chemocentryx insider trading alert for grant of common stock by Herron Jennifer Lyn, the corporate stakeholder, on 30th of June 2022. This event was filed by Chemocentryx Inc with SEC on 2022-06-30. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Chemocentryx Semi Deviation

Chemocentryx has current Semi Deviation of 4.44. Semi-deviation provides a good measure of downside risk for a equity or a portfolio. It is similar to standard deviation, but it only looks at periods where the returns are less than the target or average level.

Semi-deviation is the square root of semi-variance. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Deviation 
=  
SQRT(SV) 
 = 
4.44
SQRT = Square root notation
SV =   Chemocentryx semi variance of returns over selected period

Will Chemocentryx growth be justifiable after the rise?

Standard deviation is down to 5.1. It may hint to a possible volatility drop. Chemocentryx exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Chemocentryx individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Chemocentryx future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Chemocentryx's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Chemocentryx's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Chemocentryx Implied Volatility

Chemocentryx's implied volatility exposes the market's sentiment of Chemocentryx stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Chemocentryx's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Chemocentryx stock will not fluctuate a lot when Chemocentryx's options are near their expiration.

Our Bottom Line On Chemocentryx

When is the right time to buy or sell Chemocentryx? Buying stocks such as Chemocentryx isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis.
The bottom line, as of the 15th of June 2022, we believe that at this point, Chemocentryx is undervalued with low probability of distress within the next 2 years. Our present buy vs. sell advice on the company is Buy.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Chemocentryx. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com